New epilepsy drugs 2020

Here are some new epilepsy drugs that were approved or launched in 2020:

1. Briviact (brivaracetam): A new formulation of brivaracetam, a medication used to treat partial-onset seizures, was approved by the FDA in January 2020. The new formulation is a once-daily oral tablet that is easier to take than the previous formulation, which required a twice-daily dosing regimen.
2. Fintepla (fenfluramine): Fintepla is a new medication used to treat Dravet syndrome, a rare and severe form of epilepsy. It was approved by the FDA in June 2020 and is the first medication specifically approved for the treatment of Dravet syndrome.
3. Zeposia (ozanimod): Zeposia is a new oral medication used to treat relapsing forms of multiple sclerosis (MS), including secondary progressive MS. It was approved by the FDA in March 2020, and while not specifically approved for epilepsy, it has been shown to have anti-seizure properties in animal studies.
4. Stiripentol (Seizure Response): Stiripentol is a new medication used to treat Lennox-Gastaut syndrome (LGS), a rare and severe form of epilepsy. It was approved by the European Medicines Agency (EMA) in June 2020 and is not yet approved in the United States.
5. Epidiolex (cannabidiol): While not a new medication per se, Epidiolex, a cannabidiol (CBD) medication, received expanded approval from the FDA in June 2020 to treat Lennox-Gastaut syndrome (LGS) and Dravet syndrome, in addition to its previously approved indication for treating tuberous sclerosis complex (TSC).

These are just a few examples of new epilepsy drugs that were approved or launched in 2020. It's always important to consult with a healthcare professional before starting any new medication, including those used to treat epilepsy.